PATH announces program leader for drug development

October 8, 2014 by PATH

Dr. David Shoultz to lead work across one of PATH's five innovation platforms

PATH has named Dr. David Shoultz the leader of its Drug Development program. Based in PATH's South San Francisco office, he will direct work across the drug development portfolio and provide support and strategic input to PATH's product development leadership team.

"PATH is a leader in global health innovation, including the groundbreaking health solutions advanced by our drug development team," said Dr. David C. Kaslow, vice president for product development at PATH. "David's expertise and experience in global health and infectious disease leadership, strategy and operations, and business development, as well as his tireless passion for global health equity, will help drive and integrate our drug development work to achieve greater impact, and further our mission of saving lives and improving health."

Leader in successful global health partnerships, clinical research and development

Shoultz most recently served as the director of grantee and partner engagement at the Bill & Melinda Gates Foundation and as a member of the Gates Foundation's leadership team. In this position, he led an effort to strengthen the relationships with its partner organizations to facilitate ongoing interactions and help achieve maximum impact. Shoultz also served as a deputy director in the Gates Foundation's Global Health Program, Infectious Disease, where he was central to strategy, planning, and management for four strategic program teams, including malaria, enteric diseases, pneumonia, and neglected tropical diseases.

Shoultz has a history of working with PATH, both as the relationship manager for PATH while at the Gates Foundation, and as a board member at OneWorld Health following its establishment as a program of PATH in 2011.

Prior to his roles at the Gates Foundation, Shoultz worked as a member of the senior management team for a number of clinical research organizations participating in the development of new medicines, including PPD Development, PRA International, and Biomedical Systems. His significant experience in working with partners and creating and leading successful strategic business plans is mirrored by his deep commitment for integrated product and market development for global health impact.

Cross-sector commitment to education and innovation

Shoultz earned his PhD and MS from the University of Washington School of Public Health, where he also obtained his BSN. He holds an MBA from the Albers School of Business and Economics at Seattle University, where he is also a faculty member in the Executive MBA Program. For the past 14 years, he has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington.

Shoultz is a board member and serves as the inaugural chair of the Scientific Advisory Committee for the Geneva Foundation, a nonprofit organization that supports and advances innovative medical research and excellence in education within the U.S. military.

More information